CN105407878A - 药物组合物、制备及其用途 - Google Patents

药物组合物、制备及其用途 Download PDF

Info

Publication number
CN105407878A
CN105407878A CN201480031188.4A CN201480031188A CN105407878A CN 105407878 A CN105407878 A CN 105407878A CN 201480031188 A CN201480031188 A CN 201480031188A CN 105407878 A CN105407878 A CN 105407878A
Authority
CN
China
Prior art keywords
nanoparticles
compound
pharmaceutical composition
composition according
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480031188.4A
Other languages
English (en)
Chinese (zh)
Inventor
阿格尼丝·波迪艾尔
劳伦特·莱维
马里-艾迪斯·梅尔
奥德蕾·达尔蒙
马蒂厄·热尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuradigam
Original Assignee
Nanobiotix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix SA filed Critical Nanobiotix SA
Priority to CN202010861645.XA priority Critical patent/CN112107558A/zh
Publication of CN105407878A publication Critical patent/CN105407878A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480031188.4A 2013-05-30 2014-05-30 药物组合物、制备及其用途 Pending CN105407878A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010861645.XA CN112107558A (zh) 2013-05-30 2014-05-30 药物组合物、制备及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361828794P 2013-05-30 2013-05-30
EP13305712.5 2013-05-30
EP13305712 2013-05-30
US61/828,794 2013-05-30
PCT/EP2014/061296 WO2014191569A1 (en) 2013-05-30 2014-05-30 Pharmaceutical composition, preparation and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010861645.XA Division CN112107558A (zh) 2013-05-30 2014-05-30 药物组合物、制备及其用途

Publications (1)

Publication Number Publication Date
CN105407878A true CN105407878A (zh) 2016-03-16

Family

ID=48656009

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480031188.4A Pending CN105407878A (zh) 2013-05-30 2014-05-30 药物组合物、制备及其用途
CN202010861645.XA Pending CN112107558A (zh) 2013-05-30 2014-05-30 药物组合物、制备及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010861645.XA Pending CN112107558A (zh) 2013-05-30 2014-05-30 药物组合物、制备及其用途

Country Status (17)

Country Link
US (2) US10413509B2 (enExample)
EP (1) EP3003288A1 (enExample)
JP (1) JP6387400B2 (enExample)
KR (1) KR102245421B1 (enExample)
CN (2) CN105407878A (enExample)
AU (1) AU2014273043B2 (enExample)
BR (1) BR112015029853A2 (enExample)
CA (1) CA2913023C (enExample)
EA (1) EA038671B1 (enExample)
HK (1) HK1222563A1 (enExample)
MA (1) MA38687A1 (enExample)
MX (1) MX376269B (enExample)
NZ (1) NZ714273A (enExample)
SG (1) SG11201509436TA (enExample)
UA (1) UA116380C2 (enExample)
WO (1) WO2014191569A1 (enExample)
ZA (1) ZA201509307B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108969757A (zh) * 2018-07-11 2018-12-11 浙江大学 负载microRNA的氧化铈纳米复合水凝胶及制备方法和应用
CN110498607A (zh) * 2019-08-21 2019-11-26 中国科学院上海硅酸盐研究所 一种多功能钙硅基稀土掺杂的生物活性粉体及其制备方法和应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102025743B1 (ko) 2011-12-16 2019-09-26 나노비오?스 금속성 및 산화하프늄 소재를 포함하는 나노입자, 이의 제조 및 용도
SG11201509436TA (en) 2013-05-30 2015-12-30 Nanobiotix Pharmaceutical composition, preparation and uses thereof
JP6836510B2 (ja) 2014-11-25 2021-03-03 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 少なくとも２つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用
DK3236934T3 (da) * 2014-11-25 2024-08-19 Curadigm Sas Farmaceutisk sammensætning, fremstilling og anvendelser deraf
AR102780A1 (es) 2014-11-25 2017-03-22 Nanobiotix Composiciones farmacéuticas, su preparación y sus usos
WO2016083331A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP3258917B1 (en) * 2015-02-19 2022-12-21 Carnegie Mellon University Methods to reduce toxicities and to improve bioavailabilities of nanodrugs
EP3302419A1 (en) 2015-05-28 2018-04-11 Nanobiotix Nanoparticles for use as a therapeutic vaccine
CN105055447B (zh) * 2015-06-23 2018-03-13 中南大学湘雅二医院 氧化铁纳米颗粒用于制备改善厄洛替尼耐药性药物的应用
EP3813884B1 (en) * 2018-06-29 2024-09-18 North Carolina State University In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086639A2 (en) * 2004-02-10 2005-09-22 Barnes-Jewish Hospital Improved efficacy and safety of targeted particulate agents with decoy systems
CN1897979A (zh) * 2003-12-22 2007-01-17 伯拉考开发股份有限公司 用于反差成像的充气微囊组件
WO2007116954A2 (en) * 2006-03-30 2007-10-18 Fujifilm Corporation Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
WO2011151631A1 (en) * 2010-06-04 2011-12-08 King's College London Nanoparticles and their uses in molecular imaging

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US20030186869A1 (en) * 1990-05-14 2003-10-02 George Poiani Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US6686332B1 (en) * 1993-10-15 2004-02-03 Xoma Corporation Method of treating depressed reticuloendothelial system function
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
AU4821697A (en) 1996-10-18 1998-05-15 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice
JPH10120597A (ja) * 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
AU747051B2 (en) 1997-08-19 2002-05-09 Warner-Lambert Company Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents
US20040166060A1 (en) * 2000-06-16 2004-08-26 Sloan Kettering Institute For Cancer Research Liposomal encapsulation of alpha particle emittors and uses thereof
AU2001270413A1 (en) * 2000-06-30 2002-01-14 Inex Pharmaceuticals Corporation Improved liposomal camptothecins and uses thereof
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20050090732A1 (en) * 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
WO2006127962A2 (en) * 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
US20090130050A1 (en) 2006-03-24 2009-05-21 Toto Ltd. Titanium Oxide Composite Particles, Dispersion Liquid Thereof, and Process for Producing Them
JP2009536162A (ja) 2006-05-04 2009-10-08 ユニバーシティー オブ サウス オーストラリア ナノ粒子被覆カプセルからの薬物放出
CN101795671A (zh) 2007-08-21 2010-08-04 阿尔扎公司 用于体内施用硼酸化合物的脂质体组合物
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
EP2231765A2 (en) 2007-12-21 2010-09-29 University Of Guelph Polysaccharide nanoparticles
WO2009105774A2 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
EP2275137A1 (en) * 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
WO2011100058A1 (en) * 2010-02-09 2011-08-18 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
CN102781472B (zh) 2010-02-17 2014-07-02 国立大学法人神户大学 放射线治疗剂
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
WO2012051220A1 (en) 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
JP2014504295A (ja) 2010-12-17 2014-02-20 アローヘッド リサーチ コーポレイション ｓｉＲＮＡ用ガラクトースクラスター−薬物動態調節剤標的指向部分
EP2670393B8 (en) 2011-01-31 2016-10-05 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
CN103429227B (zh) * 2011-01-31 2017-12-19 纳米生物技术公司 纳米粒子递送系统、其制备及应用
US20120237566A1 (en) * 2011-03-15 2012-09-20 Venture Isles, LLC Inhibiting stomach-acid release, reducing inflammation and preventing and treating cancer: compositions and methods of use
US10251841B2 (en) 2011-10-17 2019-04-09 Trustees Of Boston University Polymeric depots for localization of agent to biological sites
CN102532154B (zh) 2012-01-11 2014-05-14 昆明医学院 隆萼当归线型呋喃香豆素化合物及其应用
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
SG11201509436TA (en) * 2013-05-30 2015-12-30 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
JP6836510B2 (ja) 2014-11-25 2021-03-03 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 少なくとも２つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用
DK3236934T3 (da) 2014-11-25 2024-08-19 Curadigm Sas Farmaceutisk sammensætning, fremstilling og anvendelser deraf
AR102780A1 (es) 2014-11-25 2017-03-22 Nanobiotix Composiciones farmacéuticas, su preparación y sus usos
WO2016083331A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
MX2017006813A (es) 2014-11-25 2018-01-30 Nanobiotix Composicion farmaceutica, preparacion y usos de la misma.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1897979A (zh) * 2003-12-22 2007-01-17 伯拉考开发股份有限公司 用于反差成像的充气微囊组件
WO2005086639A2 (en) * 2004-02-10 2005-09-22 Barnes-Jewish Hospital Improved efficacy and safety of targeted particulate agents with decoy systems
WO2007116954A2 (en) * 2006-03-30 2007-10-18 Fujifilm Corporation Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
WO2011151631A1 (en) * 2010-06-04 2011-12-08 King's College London Nanoparticles and their uses in molecular imaging

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张吉林，等: "单分散磁性纳米粒子靶向药物载体", 《化学进展》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108969757A (zh) * 2018-07-11 2018-12-11 浙江大学 负载microRNA的氧化铈纳米复合水凝胶及制备方法和应用
CN108969757B (zh) * 2018-07-11 2021-07-27 浙江大学 负载microRNA的氧化铈纳米复合水凝胶及制备方法和应用
CN110498607A (zh) * 2019-08-21 2019-11-26 中国科学院上海硅酸盐研究所 一种多功能钙硅基稀土掺杂的生物活性粉体及其制备方法和应用
CN110498607B (zh) * 2019-08-21 2022-03-08 中国科学院上海硅酸盐研究所 一种多功能钙硅基稀土掺杂的生物活性粉体及其制备方法和应用

Also Published As

Publication number Publication date
MX2015016456A (es) 2016-03-03
JP6387400B2 (ja) 2018-09-05
SG11201509436TA (en) 2015-12-30
JP2016522833A (ja) 2016-08-04
BR112015029853A2 (pt) 2017-07-25
EA201592279A1 (ru) 2016-06-30
HK1222563A1 (zh) 2017-07-07
US20200009050A1 (en) 2020-01-09
AU2014273043A1 (en) 2015-12-03
WO2014191569A1 (en) 2014-12-04
US20160184225A1 (en) 2016-06-30
KR20160013212A (ko) 2016-02-03
EA038671B1 (ru) 2021-10-01
CA2913023A1 (en) 2014-12-04
CN112107558A (zh) 2020-12-22
US10413509B2 (en) 2019-09-17
MA38687A1 (fr) 2017-12-29
UA116380C2 (uk) 2018-03-12
MX376269B (es) 2025-03-07
AU2014273043B2 (en) 2019-02-07
NZ714273A (en) 2019-04-26
CA2913023C (en) 2021-06-08
US11357724B2 (en) 2022-06-14
EP3003288A1 (en) 2016-04-13
ZA201509307B (en) 2017-04-26
KR102245421B1 (ko) 2021-04-29

Similar Documents

Publication Publication Date Title
US11357724B2 (en) Pharmaceutical composition, preparation and uses thereof
US11471410B2 (en) Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
US20170258718A1 (en) Pharmaceutical composition, preparation and uses thereof
Sawant et al. Cancer research and therapy: Where are we today
Chen et al. M1 macrophage-derived sonoresponsive nanoparticles for sonodynamic anticancer therapy
Chenab et al. Intertumoral and intratumoral barriers as approaches for drug delivery and theranostics to solid tumors using stimuli-responsive materials
Ahuja et al. Drug targeting approaches and use of drug delivery systems in management of cancer
HK40042656A (en) Pharmaceutical composition, preparation and uses thereof
Habra Investigating potential nano-and micro-drug delivery systems toward the non-invasive treatment of glioblastoma brain tumours
Sampaio et al. Revolutionizing Therapy: Nanomaterials in Liposomes
Seriah Development of Smart Polymeric Nanocontainers for the Therapy of Head and Brain Malignancies
Haque et al. Nanomedicines for brain targeting: A patent review
Rahman¹ et al. Liposomal nanotherapeutics in cancer
Gupta et al. Drug Targeting and Delivery
Taymoori et al. The role of nanomedicine in the treatment of osteosarcoma and in the prevention of infections
Banerjee Nanoparticles in Cancer Therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200327

Address after: Fa Guobali

Applicant after: Kuradigam

Address before: Fa Guobali

Applicant before: NANOBIOTIX

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20160316

RJ01 Rejection of invention patent application after publication